![logo for UMassMed News](/globalassets/Chancellor/Images/umassmednowlogo-small.png)
![UMass Chan, QurAlis Corporation partnership expands on biomedical research by Joel Richter](/globalassets/umass-chan-news/top-story/richter-2024-660.png?format=jpeg&quality=80)
UMass Chan, QurAlis Corporation partnership expands on biomedical research by Joel Richter
UMass Chan Medical School and QurAlis Corporation, a clinical-stage biotechnology company investigating treatments for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative and neurological diseases, have formed a collaboration to investigate an antisense oligonucleotide technology for the potential treatment of fragile X syndrome.
Category: School of Medicine,Faculty,Research,Jonathan K. Watts,RNA Therapeutics Institute,Program in Molecular Medicine,Latest News,Top Stories
Read more